Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ENCORAFENIB for Bladder cancer: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 6 adverse event reports in the FDA FAERS database where ENCORAFENIB was used for Bladder cancer.

Most Reported Side Effects for ENCORAFENIB

Side Effect Reports % Deaths Hosp.
Death 1,004 11.7% 989 60
Off label use 989 11.6% 165 186
Nausea 758 8.9% 38 213
Fatigue 685 8.0% 54 167
Diarrhoea 574 6.7% 37 221
Neoplasm progression 548 6.4% 163 107
Pyrexia 539 6.3% 34 241
Product use in unapproved indication 506 5.9% 77 63
Vomiting 429 5.0% 24 173
Rash 414 4.8% 22 83
Serous retinal detachment 297 3.5% 13 56
Arthralgia 281 3.3% 13 56
Malaise 266 3.1% 30 85
Decreased appetite 261 3.1% 32 111
Asthenia 213 2.5% 29 85

Other Indications for ENCORAFENIB

Malignant melanoma (2,591) Colon cancer (1,294) Metastatic malignant melanoma (865) Colorectal cancer metastatic (362) Colorectal cancer (289) Product used for unknown indication (241) Neoplasm malignant (199) Metastasis (168) Colon cancer metastatic (134) Thyroid cancer (115)

Other Drugs Used for Bladder cancer

BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN (1,279) PEMBROLIZUMAB (869) GEMCITABINE (841) CISPLATIN (780) ENFORTUMAB VEDOTIN-EJFV (530) NIVOLUMAB (512) ATEZOLIZUMAB (487) CARBOPLATIN (332) BACILLUS CALMETTE-GUERIN ANTIGEN, UNSPECIFIED SUBSTRAIN (326) GEMCITABINE\GEMCITABINE (240)

Related Pages

ENCORAFENIB Full Profile All Bladder cancer Drugs ENCORAFENIB Demographics ENCORAFENIB Timeline